Lung Cancer Clinical Trials

Showing 221-240 of 4,288 trials

COMPLETED

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

NCT07143513

The primary objective of this study is to characterize the safety profile of sotorasib.

Non-Small Cell Lung Cancer

Amgen102 participantsStarted Aug 2025

Qionghai, Hainan, China • Qionghai, Hainan, China • Qionghai, Hainan, China

RECRUITINGPhase 1

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

NCT06080061

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Lung Cancer

Stanford University45 participantsStarted Oct 2023

Palo Alto, California, United States • San Jose, California, United States

AVAILABLE

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

NCT06834074

The Expanded Access Program will provide an alternate mechanism for patients, who lack satisfactory therapeutic alternatives and cannot participate in a neladalkib clinical trial, to access investigational neladalkib.

Non Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)

Nuvalent Inc.

Orange, California, United States • Aurora, Colorado, United States • Chicago, Illinois, United States +40 more locations

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Related Searches

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

FL-261 Imaging for Cancer Diagnosis and Staging

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors